Biogen Q3 revenue rises 11% to $2.8 billion; GAAP loss on $284 million charge
Biogen reported third quarter 2026 total revenue of $2.8 billion, up 11% from a year earlier, with the first full quarter of Apellis products contributing. GAAP diluted EPS was $(0.14) versus $3.17 a year earlier, mainly due to transaction-related charges, and non-GAAP diluted EPS fell to $2.62 from $4.81 after a $284 million acquired IPR&D, upfront and milestone expense. The company also raised the low end of its full year 2026 non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00.
Key points
- Total revenue $2.8 billion, up 11% year over year; Growth Portfolio revenue $1.26 billion, up 49%
- GAAP diluted EPS $(0.14) vs. $3.17 a year earlier; non-GAAP diluted EPS $2.62 vs. $4.81
- $284 million acquired IPR&D, upfront and milestone expense, primarily related to the RayThera Inc. acquisition
- Full year 2026 non-GAAP diluted EPS guidance low end raised to $12.20 from $12.00; range now $12.20 to $13.00
The filing
Written by AI on Nov 7, 2026, 11:18 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.